A new $1 billion fund backed by 20 drugmakers including Merck & Co. Inc. and Pfizer Inc. is aiming to bolster struggling antibiotic companies and sustain a pipeline for new treatments.
London-based Freeline announced the closing of a $120 million extended Series C financing to advance the company’s gene therapy programs, and is considering additional capital fundraising options during 2020.
Biotech and pharmaceutical companies and health care institutions are on the front lines of not only fighting COVID-19, but working to develop vaccines and therapies against the respiratory illness – often in unexpected ways.
Unlisted German biotech firm CureVac will become the second company after rival BioNTech to launch human trials of an experimental coronavirus vaccine in the country, eyeing a potential approval in mid-2021.
Full-service health and wellness agency Fingerpaint is forming Photo 51, a new consultancy focused solely on gene and cell therapies.
Moderna confirmed plans to start a trial of 30,000 volunteers of the company’s much-anticipated coronavirus vaccine in July as the company enters the final stage of testing.
Lonza signed a partnership agreement with Anthos Therapeutics to develop and manufacture an antibody treatment for blood clots.
Exclusive: Lilly COVID-19 treatment could be authorized for use as soon as September – chief scientist (Reuters) – Eli Lilly and Co could have a drug specifically designed to treat COVID-19 authorized for use as early as September if all goes well with either of two antibody therapies it is testing, its chief scientist told […]
Biotech investor Atlas Venture has a new fund that will support the launch of startups in the industry.
The Pfizer Breakthrough Growth Initiative has been established with a $500 million investment.